ICI-199,441

ICI-199,441 is a drug that was developed by Imperial Chemical Industries (ICI) and is known for its analgesic properties. It is a kappa opioid receptor agonist, which means it binds to and activates kappa opioid receptors in the body to produce its effects.

History

ICI-199,441 was developed by the British company Imperial Chemical Industries in the late 20th century. The company, which was one of the largest chemical producers in the world, had a significant pharmaceutical division that was responsible for the development of several important drugs.

Pharmacology

ICI-199,441 is a kappa opioid receptor agonist. Opioid receptors are a group of G protein-coupled receptors with opioids as ligands. The kappa opioid receptor is one of four related receptors that bind opioid-like compounds in the brain and are responsible for mediating the effects of these compounds. These effects can include analgesia, sedation, and euphoria.

When ICI-199,441 binds to the kappa opioid receptor, it activates the receptor and produces analgesic effects. This makes it potentially useful for the treatment of pain. However, the drug also has the potential to produce side effects, including sedation and euphoria, which can limit its usefulness.

Clinical Use

While ICI-199,441 has been studied for its potential use in the treatment of pain, it is not currently approved for medical use. The drug's potential side effects, including sedation and euphoria, have limited its development.

See Also

• Imperial Chemical Industries
• Kappa opioid receptor
• Analgesic

• 
  ICI-199,441